OptiNose Standardizes on Medidata Rave Clinical Technology

Article

Company News Release

Medidata Solutions announced that its electronic data capture (EDC) and clinical data management (CDM) solution Medidata Rave has been selected by OptiNose US, Inc.to capture clinical trial data across all studies.

“The company’s selection of Rave speaks volumes about the comfort and trust in our technologies at all levels–from sponsors of all sizes to investigators across the globe.”
Founded in 2000, OptiNose is focused on the development of breakthrough bi-directional nasal drug delivery technology which significantly improves drug transport to targeted sites deep into the nasal cavity. The company is currently planning clinical research programs for the treatment of migraine headaches, nasal polyposis and chronic sinusitis. In assessing potential systems, OptiNose looked for a user-friendly, affordable EDC system that could potentially reduce time to database lock across global trials.

“The product’s ease-of-use and the company’s global presence provide benefits for our clinical development team, as well as our investigators, many of whom are familiar with the Medidata system,” commented Jennifer Carothers, senior director of clinical development, OptiNose.

Leveraging Medidata Rave’s global library to create standard electronic case report forms (eCRFs) will help OptiNose accelerate EDC set-up across their trials. Research teams, including site investigators, will also benefit from Rave’s broad data reporting capabilities, including out of the box J-Review reports for simplified ad-hoc clinical data analysis.

Recent Videos
Related Content
© 2024 MJH Life Sciences

All rights reserved.